
    
      This is a Phase 2/3, 2-part, open-label, dose-escalation, age de-escalation, randomized,
      observer-blind, placebo-controlled, expansion study intended to infer the effectiveness of
      mRNA-1273 in children aged 6 months to less than 12 years.

      Please access http://www.kidcovestudy.com for additional information, such as Study Overview,
      Participation, Site Locations along with contact numbers for each location for the study.
    
  